NCT05847049View on ClinicalTrials.gov

Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy

CompletedOBSERVATIONAL

Enrollment

16

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

March 25, 2023

Study Completion Date

April 6, 2023

Conditions

Central Serous Chorioretinopathy

Interventions

OTHER

Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

Trial Locations (1)

12311

Kasr alainy faculty of medicine, Cairo

All Listed Sponsors

lead

Dar El Oyoun Hospital

OTHER